Zobrazeno 1 - 10
of 79
pro vyhledávání: ''
Autor:
J.H. Hong, Y.S. Park, Myung Ah Lee, Sung Heon Kim, J.W. Lee, So Young Yoon, Seungtae Kim, Jung-Hun Kang, J. O. Park, Joung-Soon Jang, Byeong Seok Sohn, S.Y. Oh, Hyungwoo Lee, M. Kim, H. Y. Lim, Hye Jin Choi
Publikováno v:
Annals of Oncology. 30:788-795
Background Capecitabine plus oxaliplatin (XELOX) has shown modest activity and tolerable toxicity in a phase II trial for biliary tract cancers (BTCs). Meanwhile, gemcitabine plus oxaliplatin (GEMOX) has been the reference arm in recent phase II and
Autor:
I. Rodriguez, Antonio González-Martín, Antonio Casado, I.L. Ray-Coquard, E.M. Guerra Alia, Jérôme Alexandre, Patrick Bohan, Andres Poveda, Cristina Fernández, Dominique Berton-Rigaud, J. M. Del Campo, C. Fernandez Teruel, Magali Provansal, Carlos M. Galmarini, Carmen Kahatt, Arturo Soto, A. Perez de la Haza
Publikováno v:
Annals of Oncology
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Background PM01183 is a new compound that blocks active transcription, produces DNA breaks and apoptosis, and affects the inflammatory microenvironment. PM01183 showed strong antitumor activity in preclinical models of cisplatin-resistant epithelial
Autor:
Hildegard Christ, Martin Hellmich, A. Huth, G. Kofla, Carolin Krämer, Monika Engelhardt, C.-M. Wendtner, Kerstin Schäfer-Eckart, Maria J G T Vehreschild, Lena M Biehl, Michael G. Kiehl, Jens Panse, Meinolf Karthaus, M. Hentrich, Andrew J. Ullmann
Publikováno v:
Annals of Oncology. 27:1916-1922
Background Central venous catheter (CVC)-related bloodstream infections (CRBSI) are a frequent cause of morbidity and mortality in patients with chemotherapy-induced neutropenia. Chlorhexidine containing catheter securement dressings may prevent CRBS
Autor:
Muneharu Konishi, Y Shigeoka, Hirofumi Suwa, Yasuo Miyoshi, Shintaro Takao, Kazuhiko Yamagami, Keiko Murase, Ayako Yanai, Mayuko Miki, Masayuki Imamura, Masaru Miyashita, Toshitaka Okuno, K. Hirokaga, Kohei Akazawa
Publikováno v:
Annals of Oncology. 30:ix17-ix18
Background When considering treatment for metastatic and recurrent breast cancer, it is necessary to select drugs with emphasis on side effects and QOL. In Japan, oral 5-FU drugs have often been used for initial treatment. In the conventional schedul
Autor:
Vsevolod Matveev, A. Bulanov, Maria Volkova, S. A. Tjulandin, T. Zakharova, Y. Segeev, A. Chekini, O. Sekhina, A. Garin, D. Chekini, B. Akhmedov, Tryakin, A. Klimov, I. Fainstein, S. Menshikova, Mikhail Fedyanin
Publikováno v:
Annals of Oncology. 30:v398-v399
Background Three-weekly BEP has been a standard of CT of advanced NSGCT for last two decades. We performed a phase II study to assess the efficacy and toxicity of two-weekly aBEP regimen in the first line treatment of NSGCT. Here we report final effi
Autor:
Y. Nakamura, N. Hirano, Akihito Kawazoe, Masashi Wakabayashi, Miki Fukutani, Sachiyo Nomura, A. Sato, Daisuke Takahari, K. Shitara, H. Tamura
Publikováno v:
Annals of Oncology. 30:v303-v304
Background High deoxyuridine triphosphatase (dUTPase) in tumor tissue, as a gatekeeper enzyme for 5-fluorouracil (5-FU), is associated with 5-FU resistance. TAS-114 is an oral dUTPase inhibitor which enhance antitumor activity with 5-FU or fluoropyri
Autor:
Hironaga Satake, N. Tanaka, T. Watanabe, T. Kato, Hiroaki Tanioka, T. Kyogoku, Keitaro Shimozaki, M. Tatsumi, Masato Matsuura, Akihito Tsuji, Masahito Kotaka, Yasuo Oka, K. Matoba, Akira Miki, Kenro Hirata, Shinichi Adachi, Hisateru Yasui
Publikováno v:
Annals of Oncology. 30:v302-v303
Background Prognosis for locally advanced gastric cancer (LAGC), such as clinical T4 disease, bulky nodal metastases, type 4 and large type 3 gastric cancer, was not satisfactory even by D2 gastrectomy followed by adjuvant chemotherapy. Neoadjuvant c
Autor:
Hussain Alhussain, Eyad Alsaeed, Fouad H AlNajjar, Ali Abdullah O Balbaid, Waleed Ali Alghareeb, Yassir Orz, Abdullah A Alsharm, Abdullah Altwairgi, Ahmed Lary, Sadeq Al-Dandan
Publikováno v:
Annals of Oncology. 30:ix20
Background Glioblastoma is the one of most fast-growing primary brain tumor in adult and it carries the worst prognosis. Atorvastatin is an inhibitor of HMG-CoA reductase, a rate-limiting enzyme in the mevalonate pathway. Preclinical studies demonstr
Autor:
Takuya Miyagi, Takeru Funakoshi, Yuki Yamamoto, Taku Fujimura, K. Yoshino, Shigeto Matsushita, Atsushi Otsuka, Hironobu Hata, Hiroshi Uchi, Yasuhiro Fujisawa
Publikováno v:
Annals of Oncology. 30:ix135
Background Although taxanes (TAX) are effective for advanced cutaneous angiosarcoma (CAS) and stand as a current first-line treatment, no standardized second-line treatment has yet been established. Eribulin methylate (ERB), a non-taxane microtubule
Autor:
Junji Suzumiya, Jun Yamanouchi, Akinao Okamoto, Shingen Nakamura, Tatsuo Oyake, Itaru Matsumura, Hiroki Yamaguchi, Yoshio Saburi, Moritaka Gotoh, Kazuo Tamura, Masaki Iino, Hiroyuki Fujita, Yoshinobu Kanda, Souichi Shiratori, Takahiro Fukuda, Shin-ichiro Fujiwara, Yasushi Takamatsu, Emiko Sakaida, Shun-ichi Kimura
Publikováno v:
Annals of Oncology. 30:vi84
Introduction Empiric antifungal therapy (EAT) is recommended for persistent febrile neutropenia (FN) based on some large-scale randomized studies. However, EAT sometimes results in overtreatment and unnecessary expense. On the other hand, preemptive